Catalyst Dossier · compiled by CeliA 🧫
Deciphera Pharmaceuticals, Inc. (DCPH)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
9
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-03-15 (est.)Phase 2 · Inlexisertibimp 7/10
- 2027-03-15 (est.)Phase 2 · Ripretinibimp 7/10
- 2027-08-15 (est.)Phase 2 · Inlexisertibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ripretinib | Phase 3 | GIST |
| Vimseltinib | Phase 3 | Chronic Graft-Versus-Host Disease (cGVHD) |
| DCC-2618 | Phase 3 | Gastrointestinal Stromal Tumors |
| DCC-3084 | Phase 2 | Advanced Solid Tumor |
| DCC-3009 | Phase 2 | Gastrointestinal Stromal Tumor (GIST) |
| Inlexisertib | Phase 2 | Non-Small Cell Lung Cancer |
| Sapablursen | Phase 3 | Polycythemia Vera |
| Tirabrutinib | Phase 3 | Relapsed/Refractory Primary Central Nervous System Lymphoma |
| Sunitinib | Phase 3 | Gastrointestinal Stromal Tumors |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DCPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.